Abstract: Methods and model equations are provided for predicting a risk of a subject who experiences adverse medical events associated with the weather, of experiencing a new-onset event.

Abstract: A method to treat pneumothorax or malignant pleural effusion by pleurodesis in a mammalian subject is disclosed. The method involves administering particles to the lungs, the pleural space or both. The particles comprise a crystalline material that is non-toxic and is cleared over time by biodegradation. In some embodiments, the biodegraded crystalline material is readily cleared by the kidneys. In one embodiment, the crystalline material is essentially cleared from the lungs a few months after treatment.

Abstract: A cocrystal complex of pirfenidone with a polyphenolic macrocycle host is disclosed. The composition is useful, in some embodiments, as an acne treatment. In one embodiment, the macrocycle is calixarene or a calixarene derivative. In another embodiment, the macrocycle is resorcin[4]arene. In one embodiment, the macrocycle is C-methylresorcin[4]arene (RsC1). In another embodiment, the macrocycle is C-butylresorcin[4]arene (RsC4).

Abstract: A system 100, 200 for sensing one or more analytes in a first biofluid and a second biofluid and methods of using said system. The system 100, 200 may include a first subsystem 102, 200a, 200b with a first sensor 120, 122, 220, 222 for sensing a first analyte in the first biofluid and a second subsystem 104, 200b, 200c with a second sensor 124, 126, 222, 224 for sensing a second analyte in the second biofluid. The second analyte may be the same as or different from the first analyte and the second biofluid may be different from the first biofluid. In an embodiment, the first biofluid is a non-sweat biofluid and the second biofluid is sweat. The system 100, 200 may be used to detect lag time for measuring an analyte in one of the biofluids.

Abstract: Methods, processing systems, and computer-readable mediums for automated designing of patient-specific cranial implants may include extracting pixel data from a DICOM file; generating a virtual skull model based on the pixel data; identifying a mid-sagittal plane of the virtual skull model; identifying a surgical hole in the virtual skull model; mirroring a reference side of the virtual skull model onto a surgical hole side of the virtual skull model; subtracting the surgical hole side from the mirrored reference side to generate a virtual cranial implant; and generating a virtual two-part mold based on the virtual cranial implant. A physical two-part mold can be 3D printed based on the virtual two-part mold, and a physical cranial implant can be constructed using the physical two-part mold.

Abstract: The method of covalently bonding carbon nanotubes to substrates is provided. The method comprises functionalizing a substrate and each open-end of a plurality of open-ended carbon nanotubes, embedding each of the plurality of open-ended carbon nanotubes within respective polymers, aligning, orthogonally, the plurality of open-ended carbon nanotubes relative to the substrate, and applying pressure on each of the plurality of open-ended carbon nanotubes relative to the substrate for enabling covalent bonding of each of the plurality of open-ended carbon nanotubes to the substrate.

Abstract: Small molecule inhibitors (SMIs) of the Prolactin receptor, pharmaceutical compositions of the SMIs, and methods for treating patients suffering from disorders characterized increased expression or excitation of the Prolactin receptor, including breast cancer, prostate cancer and nociceptive pain disorders such as migraine headache, by administering pharmaceutical compositions of SMIs are provided.

Abstract: A method for motion correction of Magnetic Resonance (MR) images is provided. The method includes acquiring a k-space dataset for an object using an MR scanner, detecting or identifying corrupted k-space data from the acquired k-space dataset, extracting the corrupted k-space data from the acquired k-space dataset, recovering the corrupted k-space data, combining uncorrupted k-space data of the acquired k-space dataset with the recovered k-space data to form a full k-space dataset, and reconstructing an image for the object based on the full k-space dataset. A magnetic resonance imaging system for correcting corrupted k-space data of an entire k-space dataset is also provided.

Abstract: Controlled release hydrogel formulations of one or more simvastatin metabolites 3?-hydroxy simvastatin (hSV), 6?-exomethylene simvastatin (eSV), 3?,5?-dihydrodiol simvastatin, 3?,5?-dihydrodiol simvastatin (dSV), simvastatin-beta-hydroxy acid (SVA), and methods for the treatment of patients suffering from injured or degenerating substantially avascular cartilaginous tissue.

Abstract: A method of reducing the incidence of hypoglycemia in an insulin-requiring subject is provided. The subject is administered insulin either via regular doses of insulin or via continuous subcutaneous infusion. The method involves administering to the subject C-peptide in conjunction with at least a portion of the administered insulin, where the insulin dosage is not reduced from the subject’s regular dosage as a result of the administration of C-peptide.

Abstract: A system for modulating operation of an organ in real time by controlling illumination of one or more light components is provided. The system includes an external device comprising a processing unit and a power supply configured to transmit stimulation parameters, a wireless implantable device comprising, a sensor configured to detect, in real time, activity data from a tissue cluster of an organ, a stimulator including a plurality of light components corresponding to at least a first wavelength and a second wavelength and a flexible elastomer coupled to the plurality of light components, and a transceiver configured to transmit the activity data to the external device, wherein the stimulator is configured to illuminate, based on the stimulation parameters, one of the plurality of light components coupled to the flexible elastomer, wherein the processing unit is configured to update the stimulation parameters based on the activity data.

Abstract: A method for k-space registration is provided. The method of k-space registration includes receiving a first partial k-space dataset for an object and a second partial k-space dataset for the object, selecting the first partial k-space dataset as a reference, selecting feature for estimating a transformation matrix for transforming k-space data, estimating a transformation matrix based on the feature of entire or part of the first partial k-space dataset and the feature of the second partial k-space dataset corresponding to the entire or part of the first partial k-space dataset, correcting the second partial k-space dataset based on the transformation matrix, and obtaining the corrected second partial k-space dataset. The present method is further used for partial Fourier reconstruction.

Abstract: A device and method including at least one electrochemical aptamer sensor for small sample volume sensing. The device (100) includes at least one substrate (110) that defines a microfluidic feature (118) having a defined volume. At least one electrochemical aptamer sensor (120), including an electrode (122) associated with a plurality of aptamers (124), is carried by the substrate and is in fluid communication with the defined volume. The defined volume is capable of containing less than 30 ?L of a sample fluid when the defined volume is filled with the sample fluid. Additionally, or alternatively, the volume of the sample fluid in ?L is equal to C * the surface area of the electrode in cm2 that is associated with the plurality of aptamers/concentration of the target analyte in ?M; and C has a value chosen from less than 4, less than 0.4, less than 0.04, and less than 0.004.

Abstract: A device and method for detecting the presence of, or measuring the amount or concentration of, at least one analyte in a sample fluid, where the device includes a dissolvable material, and a plurality of aptamers disposed in and/or on the dissolvable material, and where one or more aptamers of the plurality of aptamers (1) are capable of binding at least one analyte, and (2) have at least one redox tag attached thereto.

Abstract: A method is provided for prognosing a risk in a patient diagnosed with a premalignant lesion of the breast of the lesion progressing to breast cancer, the method comprising: providing a tissue sample of the premalignant lesion; detecting one or more variants of Osteopontin (OPN) selected from OPN-a, OPN-b and OPN-c in the sample; and prognosing an elevated risk of the lesion progressing to breast cancer if OPN-b and/or OPN-c is detected and/or OPN-a is elevated above normal levels in the tissue sample. Methods of assessing risk of death from breast cancer, methods of treatment, and kits for prognosis are also provided herein.

Abstract: A method of non-invasively diagnosing and treating a cancer characterized by high surface phosphatidylserine (PS) expression in a subject in need thereof is provided, the method including: obtaining a liquid biological sample from the subject; detecting a presence of cancer-secreted soluble phosphorylated Heat shock protein-70 (Hsp70) in the liquid biological sample; diagnosing the subject with a cancer characterized by high surface PS expression when cancer-secreted soluble phosphorylated Hsp70 is present in the liquid biological sample; and administering an anti-cancer therapy targeted to high surface PS expressing-cancers to the diagnosed subject. Also provided is a method for monitoring therapeutic efficacy of a treatment in a subject with a cancer characterized by high surface PS expression.

Abstract: A laminate which can serve as either a smart window or a smart mirror is formed using first and second substrates coated with transparent first and second electrodes which are separated by foraminous layer and a third grid-like linear electrode insulated from the first and second electrodes. The foraminous layer includes spacers defining a cell space which is filled with a colloidal ink having first and second particles. The first particles have a positive charge and a first color and second particles having a negative charge and a second color different from the first color. By altering the voltages of the first, second and third electrodes, one can achieve different light transmission characteristics which, for example, can alter the color temperature of the light transmitted through the laminate or enhance reflective colors.

Abstract: A rotating detonation combustor includes a nozzle coupled to the combustor body at or near the exhaust opening to choke the exhaust opening. A rotating detonation combustor may include a diverting plate positioned radially inward of the inlet annulus and inlet channels for diverting flow of a mixture in an axial direction. A rotating detonation combustor may include a combustor body including an outer shell at least partially defining a detonation combustion chamber and extending axially from a base toward an exhaust opening of the detonation combustion chamber. The base defines a passageway in fluid communication with the detonation combustion chamber and includes an inlet annulus for axially directing a second fluid into the passageway and a plurality of inlet channels for radially directing a third fluid into at least one of the passageway or the detonation combustion chamber, and the detonation combustion chamber is free of any inner body.

Abstract: A method for slowing the progression of amyotrophic lateral sclerosis (ALS) in an adult subject in need thereof is provided herein, the method including inhibiting motor neuron degeneration by administering to the subject a modified adeno-associated virus (AAV) vector having a recombinant AAV (rAAV)-based genome with an AAV backbone, a control element, and a ciliary neurotrophic factor receptor alpha (CNTFR?) cDNA insert, wherein the modified AAV vector is engineered to direct enhanced skeletal muscle expression of CNTFR?.

Abstract: Controlled release hydrogel formulations of one or more simvastatin metabolites 3?-hydroxy simvastatin (hSV), 6?-exomethylene simvastatin (eSV), 3?,5?-dihydrodiol simvastatin, 3?,5?-dihydrodiol simvastatin (dSV), simvastatin-beta-hydroxy acid (SVA), and methods for the treatment of patients suffering from injured or degenerating substantially avascular cartilaginous tissue.